Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.
While other companies have been hit with heftier fines for falsely marketing their drugs, Purdue Pharma's $700.6 million agreement with the Department of Justice over OxyContin promotions has had a profound impact on the management of the company, with guilty pleas from two of the firm's top executives
You may also be interested in...
Purdue's rise and fall through opioids will likely end in bankruptcy, raising new questions around ongoing lawsuits and shining a light on the toll the opioid liability will leave on the industry.
US court orders firms to release information on all opioid products ever classified as Schedule II from one year prior to launch date; government, manufacturers oppose public disclosure of DEA distribution data.
Task force will target unlawful marketing by opioid manufacturers, assist state lawsuits, and seek compensation for costs of opioid crisis.